Phuturdex › Diseases › Joint Diseases
Drugs in development · updated 30 October 2026
Joint Diseases: drugs in development
As of 30 October 2026 there are 4 active clinical trials (recruiting or ongoing, phases I–III) on 6 drugs for joint Diseases. 0 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AdalimumabHadlima, Simlandi® | III | 1 | NCT02629159 |
| DeucravacitinibBMS-986165, Sotyktu® | III | 1 | NCT04908202 |
| OrforglipronFoundayo® | III | 1 | NCT07153471 |
| UpadacitinibRinvoq Lq®, Rinvoq® | III | 1 | NCT02629159 |
| BupivacaineExparel, Bupivacain | II | 1 | NCT07839195 |
| DexamethasoneDexametasone, Dextenza | II | 1 | NCT07839195 |
Sorted by most advanced phase and number of active trials.
All 6 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Rheumatoid arthritis 130 drugs
- Knee osteoarthritis 37 drugs
- Psoriatic arthritis 48 drugs
- Systemic lupus erythematosus 178 drugs
- Sjogren's Syndrome 29 drugs
- Arthritis, Juvenile 39 drugs
- Systemic scleroderma 77 drugs
- Osteoarthritis 20 drugs
- Autoimmune disease 94 drugs
- Myositis 42 drugs
- Gout 13 drugs
- Arthritis 13 drugs
Broader categories
- Skin and connective tissue diseases 3 drugs
- Musculoskeletal disorder 22 drugs
- Rheumatic Diseases 30 drugs
- Nutritional and metabolic diseases 5 drugs
- Overweight 139 drugs
- Human body weight 13 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D007592 “Joint Diseases”.